端粒维持在神经母细胞瘤发病机制中的研究进展
Research Progress of Telomere Maintenance in the Pathogenesis of Neuroblastoma
DOI: 10.12677/ACM.2023.132232, PDF,   
作者: 王振华, 李万富*：新疆医科大学第一附属医院小儿普外科，新疆 乌鲁木齐
关键词: 神经母细胞瘤；端粒；端粒酶；发病机制；端粒维持；Neuroblastoma； Telomeres； Telomerase； Pathogenesis； Telomere Maintenance
摘要: 端粒被广泛认为是细胞的“有丝分裂钟”，并作为生物衰老的标志而存在。保持端粒长度高于临界阈值是恶性肿瘤细胞永生的关键，也是成人和儿童癌症发生的关键因素。最新研究显示神经母细胞瘤中端粒的维持(TMM)，无论是由端粒酶或ALT激活，都是神经母细胞瘤(NB)高危疾病的决定性标志。本文对端粒异常在神经母细胞瘤发病机制中的作用进行总结，为神经母细胞瘤疾病的临床诊治提供新的研究方向。
Abstract: Telomeres are widely regarded as the “mitotic clock” of the cell and serve as markers of biological aging. Keeping telomere length above the critical threshold is the key to the immortalization of ma-lignant tumor cells and a key factor in the development of cancer in adults and children. Recent studies have shown that telomere maintenance in neuroblastoma, whether activated by telomerase or ALT, is a definitive marker of neuroblastoma risk disease. This article summarizes the role of te-lomere abnormalities in the pathogenesis of neuroblastoma and provides a new research direction for the clinical diagnosis and treatment of neuroblastoma disease.
文章引用：王振华, 李万富. 端粒维持在神经母细胞瘤发病机制中的研究进展[J]. 临床医学进展, 2023, 13(2): 1679-1684. https://doi.org/10.12677/ACM.2023.132232

参考文献

[1] 朱呈光, 贺湘玲, 汤止戈, 等. 44例儿童神经母细胞瘤临床分析[J]. 中国当代儿科杂志, 2020, 22(11): 1193-1197.
[2] Chung, C., Boterberg, T., Lucas, J., et al. (2021) Neuroblastoma. Pediatr Blood Cancer, 68, e28473. [Google Scholar] [CrossRef] [PubMed]
[3] Brodeur, G.M. (2003) Neuroblastoma: Biological Insights into a Clinical Enigma. Nature Reviews Cancer, 3, 203-216. [Google Scholar] [CrossRef] [PubMed]
[4] Matthay, K.K., Maris, J.M., Schleiermacher, G., et al. (2016) Neuroblastoma. Nature Reviews Disease Primers, 2, 16078. [Google Scholar] [CrossRef] [PubMed]
[5] 鲁冬芳, 陈希, 舒强. 高危神经母细胞瘤分子遗传学特征研究进展[J]. 中华小儿外科杂志, 2021, 42(1): 81-7.
[6] 韩森, 马旭, 方健. 端粒与端粒酶研究在肺癌中的临床应用前景与挑战[J]. 中国肺癌杂志, 2021, 24(1): 25-30.
[7] Shay, J.W. and Wright, W.E. (2019) Telomeres and Telomerase: Three Decades of Progress. Nature Reviews Genetics, 20, 299-309. [Google Scholar] [CrossRef] [PubMed]
[8] Robinson, N.J. and Schiemann, W.P. (2022) Telomerase in Can-cer: Function, Regulation, and Clinical Translation. Cancers (Basel), 14, 201. [Google Scholar] [CrossRef] [PubMed]
[9] Dogan, F. and Forsyth, N.R. (2021) Telomerase Regulation: A Role for Epigenetics. Cancers (Basel), 13, 1213. [Google Scholar] [CrossRef] [PubMed]
[10] Kim, N.W., Piatyszek, M.A., Prowse, K.R., et al. (1994) Specific Association of Human Telomerase Activity with Immortal Cells and Cancer. Science, 266, 2011-2015. [Google Scholar] [CrossRef] [PubMed]
[11] Bejarano, L., Bosso, G., Louzame, J., et al. (2019) Multiple Cancer Pathways Regulate Telomere Protection. EMBO Molecular Medicine, 11, e10292. [Google Scholar] [CrossRef] [PubMed]
[12] Varela, E. and Blasco, M.A. (2009) Nobel Prize in Physiology or Medicine: Telomeres and Telomerase. Oncogene, 29, 1561-1565. [Google Scholar] [CrossRef] [PubMed]
[13] Smith, L., Luchini, C., Demurtas, J., et al. (2019) Telomere Length and Health Outcomes: An Umbrella Review of Systematic Reviews and Meta-Analyses of Observational Studies. Ageing Research Reviews, 51, 1-10. [Google Scholar] [CrossRef] [PubMed]
[14] Hägg, S., Zhan, Y., Karlsson, R., et al. (2017) Short Telomere Length Is Associated with Impaired Cognitive Performance in European Ancestry Cohorts. Translational Psychiatry, 7, e1100. [Google Scholar] [CrossRef] [PubMed]
[15] Haycock, P.C., Burgess, S., Nounu, A., et al. (2017) Association between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study. JAMA Oncology, 3, 636-651. [Google Scholar] [CrossRef] [PubMed]
[16] Zachek, C.M., Miller, M.D., Hsu, C., et al. (2015) Children’s Cancer and Environmental Exposures: Professional Attitudes and Practices. Journal of Pediatric Hematology/Oncology, 37, 491-497. [Google Scholar] [CrossRef] 
[17] Ackermann, S., Cartolano, M., Hero, B., et al. (2018) A Mechanistic Classification of Clinical Phenotypes in Neuroblastoma. Science, 362, 1165-1170. [Google Scholar] [CrossRef] [PubMed]
[18] Dagg, R.A., Pickett, H.A., Neumann, A.A., et al. (2017) Extensive Proliferation of Human Cancer Cells with Ever-Shorter Telomeres. Cell Reports, 19, 2544-2556. [Google Scholar] [CrossRef] [PubMed]
[19] Lin, S.Y. and Elledge, S.J. (2003) Multiple Tumor Suppressor Pathways Negatively Regulate Telomerase. Cell, 113, 881-889. [Google Scholar] [CrossRef] 
[20] Bell, R.J., Rube, H.T., Xavier-Magalhães, A., et al. (2016) Understanding TERT Promoter Mutations: A Common Path to Immortality. Molecular Cancer Research, 14, 315-323. [Google Scholar] [CrossRef] 
[21] Brady, S.W., Liu, Y., Ma, X., et al. (2020) Pan-Neuroblastoma Analysis Reveals Age- and Signature-Associated Driver Alterations. Nature Communications, 11, 5183. [Google Scholar] [CrossRef] [PubMed]
[22] Kang, J.U., Koo, S.H., Kwon, K.C., et al. (2008) Gain at Chromosomal Region 5p15.33, Containing TERT, Is the Most Frequent Genetic Event in Early Stages of Non-Small Cell Lung Cancer. Cancer Genetics and Cytogenetics, 182, 1-11. [Google Scholar] [CrossRef] [PubMed]
[23] Peifer, M., Hertwig, F., Roels, F., et al. (2015) Telomer-ase Activation by Genomic Rearrangements in High-Risk Neuroblastoma. Nature, 526, 700-704. [Google Scholar] [CrossRef] [PubMed]
[24] Martínez, P. and Blasco, M.A. (2011) Telomeric and Extra-Telomeric Roles for Telomerase and the Telomere-Binding Proteins. Nature Reviews Cancer, 11, 161-176. [Google Scholar] [CrossRef] [PubMed]
[25] Saretzki, G. (2014) Extra-Telomeric Functions of Human Telomerase: Cancer, Mitochondria and Oxidative Stress. Current Pharmaceutical Design, 20, 6386-6403. [Google Scholar] [CrossRef] [PubMed]
[26] Koh, C.M., Khattar, E., Leow, S.C., et al. (2015) Te-lomerase Regulates MYC-Driven Oncogenesis Independent of Its Reverse Transcriptase Activity. Journal of Clinical Investigation, 125, 2109-2122. [Google Scholar] [CrossRef] 
[27] Park, J.I., Venteicher, A.S., Hong, J.Y., et al. (2009) Telomerase Modulates Wnt Signalling by Association with Target Gene Chromatin. Nature, 460, 66-72. [Google Scholar] [CrossRef] [PubMed]
[28] Ghosh, A., Saginc, G., Leow, S.C., et al. (2012) Telomerase Directly Regulates NF-κB-Dependent Transcription. Nature Cell Biology, 14, 1270-1281. [Google Scholar] [CrossRef] [PubMed]
[29] Khattar, E. and Tergaonkar, V. (2017) Transcriptional Regulation of Te-lomerase Reverse Transcriptase (TERT) by MYC. Frontiers in Cell and Developmental Biology, 5, 1. [Google Scholar] [CrossRef] [PubMed]
[30] Schaub, F.X., Dhankani, V., Berger, A.C., et al. (2018) Pan-Cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Cell Systems, 6, 282-300.e2.
[31] Yu, E.Y., Cheung, N.V. and Lue, N.F. (2022) Connecting Telomere Maintenance and Regulation to the Developmental Origin and Differentiation States of Neuroblastoma Tumor Cells. Journal of Hematology & Oncology, 15, 117. [Google Scholar] [CrossRef] [PubMed]
[32] Hartlieb, S.A., Sieverling, L., Nadler-Holly, M., et al. (2021) Alternative Lengthening of Telomeres in Childhood Neuroblastoma from Genome to Proteome. Nature Communications, 12, 1269. [Google Scholar] [CrossRef] [PubMed]
[33] Meeser, A., Bartenhagen, C., Werr, L., et al. (2022) Reliable Assessment of Telomere Maintenance Mechanisms in Neuroblastoma. Cell & Bioscience, 12, 160. [Google Scholar] [CrossRef] [PubMed]
[34] Zeineldin, M., Federico, S., Chen, X., et al. (2020) MYCN Am-plification and ATRX Mutations Are Incompatible in Neuroblastoma. Nature Communications, 11, 913. [Google Scholar] [CrossRef] [PubMed]
[35] Nakagawara, A., Li, Y., Izumi, H., et al. (2018) Neuroblastoma. Japanese Journal of Clinical Oncology, 48, 214-241. [Google Scholar] [CrossRef] [PubMed]
[36] Ackermann, S. and Fischer, M. (2019) Telomere Maintenance in Pediatric Cancer. International Journal of Molecular Sciences, 20, 5836. [Google Scholar] [CrossRef] [PubMed]
[37] Koneru, B., Lopez, G., Farooqi, A., et al. (2020) Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma. Cancer Research, 80, 2663-2675. [Google Scholar] [CrossRef] 
[38] Cheung, N.K., Zhang, J., Lu, C., et al. (2012) Association of Age at Diagnosis and Genetic Mutations in Patients with Neuro-blastoma. JAMA, 307, 1062-1071. [Google Scholar] [CrossRef] [PubMed]
[39] Yu, E.Y., Cheung, I.Y., Feng, Y., et al. (2019) Telomere Trimming and DNA Damage as Signatures of High Risk Neuroblastoma. Neoplasia, 21, 689-701. [Google Scholar] [CrossRef] [PubMed]
[40] Rivera, T., Haggblom, C., Cosconati, S., et al. (2017) A Balance between Elongation and Trimming Regulates Telomere Stability in Stem Cells. Nature Structural & Molecular Biology, 24, 30-39. [Google Scholar] [CrossRef] [PubMed]
[41] Moreno, L., Barone, G., Dubois, S.G., et al. (2020) Accelerat-ing Drug Development for Neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblas-toma. European Journal of Cancer, 136, 52-68. [Google Scholar] [CrossRef] [PubMed]
[42] Roderwieser, A., Sand, F., Walter, E., et al. (2019) Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in Neuroblastoma. JCO Precision Oncology, 3, 1-20. [Google Scholar] [CrossRef] 
[43] Gomez, D.L., Armando, R.G., Cerrudo, C.S., et al. (2016) Telomerase as a Cancer Target. Development of New Molecules. Current Topics in Medicinal Chemistry, 16, 2432-2440. [Google Scholar] [CrossRef] [PubMed]
[44] Wade, M., Fox, N.A., Zeanah, C.H., et al. (2020) Te-lomere Length and Psychopathology: Specificity and Direction of Effects within the Bucharest Early Intervention Project. Journal of the American Academy of Child & Adolescent Psychiatry, 59, 140-148.e3. [Google Scholar] [CrossRef] [PubMed]

为你推荐